Details of the Drug Pharmacogenomic Perturbation Atlas

General Information of Drug (ID: DM2EMCW)

Drug Name
Antimycin A Drug Info
Synonyms
Antimycin A; Antipiricullin; Fintrol; Virosin; Antimycin A1b; antimycin A1; Caswell No. 052B; Antimycin-A; CCRIS 924; HSDB 6417; UNII-75G3NMU1TS; EPA Pesticide Chemical Code 006314; 75G3NMU1TS; CHEMBL211501; CHEBI:22584; 1397-94-0; (2R,3S,6S,7R,8R)-3-[(3-formamido-2-hydroxybenzoyl)amino]-8-hexyl-2,6-dimethyl-4,9-dioxo-1,5-dioxonan-7-yl 3-methylbutanoate; 642-15-9; 116095-18-2; [(2r,3s,6s,7r,8r)-3-[(3-Formamido-2-Oxidanyl-Phenyl)carbonylamino]-8-Hexyl-2,6-Dimethyl-4,9-Bis(Oxidanylidene)-1,5-Dioxonan-7-Yl] 3-Methylbutanoate
Cross-matching ID
PubChem CID
14957
ChEBI ID
CHEMBL211501
CAS Number
CAS 1397-94-0
TTD Drug ID
D04LBT

Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)
Term Name NES FDR q-val Tag % Leading Edge Genes
DNA replication 2.06 1.06e-2 34/36 (94.44%) RFC2;RFC4;POLE2;...
Cell cycle 2.06 5.32e-3 110/124 (88.71%) CDC20;CDC25B;CDK2;...
Bladder cancer 1.83 4.61e-2 40/41 (97.56%) MYC;ERBB2;THBS1;...
AGE-RAGE signaling pathway in diabetic complications 1.82 3.99e-2 97/100 (97%) F3;AGT;PLCB3;...
Renin-angiotensin system 1.78 3.83e-2 20/23 (86.96%) ANPEP;AGT;ENPEP;...
Allograft rejection -1.71 4.95e-2 32/38 (84.21%) IFNG;HLA-DQB1;HLA-G;...
Antigen processing and presentation -1.76 2.83e-2 60/78 (76.92%) CTSS;HLA-A;HLA-DRA;...
Autophagy -1.76 3.30e-2 113/169 (66.86%) RB1CC1;LAMP2;DDIT4;...
Oxidative phosphorylation -1.80 2.07e-2 93/133 (69.92%) ATP6AP1;NDUFB8;NDUFA9;...
Vibrio cholerae infection -1.81 2.59e-2 44/50 (88%) ATP6AP1;ATP6V1B2;ATP6V0A4;...
Phagosome -1.86 1.57e-2 118/152 (77.63%) HLA-DQB1;HLA-G;HLA-DMB;...
Fatty acid biosynthesis -1.87 2.35e-2 16/18 (88.89%) ACSBG2;MCAT;ACACB;...
Protein processing in endoplasmic reticulum -2.10 0.00e+0 127/171 (74.27%) DNAJC3;MBTPS2;CUL1;...
×

Pharmacogenomic Perturbation Across Diseases and Tissues

Breast
Breast adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MCF7 CVCL_0031 Homo sapiens 10uM 6H, 24H
Colon
Colorectal adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HT-29 CVCL_0320 Homo sapiens 10uM 6H
Hematopoietic system
Normal
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
ASC CVCL_U602 Homo sapiens 10uM 24H
Kidney
Normal (Immortalized)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HA1E CVCL_0284 Homo sapiens 10uM 6H
Normal (Transformed)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
1HAEo- CVCL_0128 Homo sapiens 10uM 24H
NL20 CVCL_0461 Homo sapiens 10uM 24H
Liver
Hepatoblastoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
Hep G2 CVCL_0027 Homo sapiens 10uM 6H
Lung
Lung adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A549 CVCL_0023 Homo sapiens 10uM 6H, 24H
Non-small cell lung carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HCC515 CVCL_5134 Homo sapiens 10uM 6H
Normal (Fibroblast)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HFL1 CVCL_4295 Homo sapiens 10uM 24H
IMR-90 CVCL_0347 Homo sapiens 10uM 24H
WI-38 CVCL_0579 Homo sapiens 10uM 24H
Prostate
Prostate carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
PC-3 CVCL_0035 Homo sapiens 1.11uM - 10uM 6H, 24H
VCaP CVCL_2235 Homo sapiens 10uM 6H, 24H
Skin
Melanoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A-375 CVCL_0132 Homo sapiens 1.11uM - 10uM 6H, 24H